Onxeo

Regulatory Filings • Sep 8, 2015

Onxeo to present at InvestorDagen 2015 The largest Danish private investor event September 22, 2015, Radisson Blu Scandinavia Hotel, Copenhagen

Paris (France), Copenhagen (Denmark), September 8, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, will be presenting at InvestorDagen 2015, which will be held in Copenhagen, Denmark on September 22, 2015 at the Radisson Blu Scandinavia Hotel.

InvestorDagen is hosted by the Danish Shareholders' Association (Dansk Aktionærforening), an association with 12,000 members. With around 2,500 participants each year, InvestorDagen is the largest event for private investors in Denmark.

Onxeo's Chief Financial Officer, Nicolas Fellmann, will give a presentation of the Company, its key strengths, its strategy based on advanced orphan oncology products, and the mid-term news flow, which is expected to drive the company's value and future growth. You will furthermore be able to meet face-to-face with representatives from the company's management team at the Onxeo stand.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (clonidine Lauriad® ): Phase II in severe oral mucositis: Positive final results Beleodaq® (belinostat): Registered in the US in 2nd line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com

To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/ Follow us on twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO j.greciet@onxeo.com Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie onxeo@alizerp.com +33 6 64 18 99 59 / +33 6 47 38 90 04